OraSure Technologies, Inc. Aktie News

BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.

Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc....

Altai Capital Management is preparing to launch a board fight at OraSure Technologies after the hedge fund, already one of the biggest owners of the medical device maker, increased its holdings, two people familiar with the matter told Reuters.

Prominent healthcare entrepreneur Ron Zwanziger warned on Monday he may pursue a more "adversarial path" if the OraSure Technologies board continues to resist his offer to buy the medical devices company, according to a letter seen by Reuters.

OraSure (OSUR) Q2 Revenue Falls 43%

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Carrie Eglinton Manner - President, CEO & Director Jason Michael Plagman - Vice President of Investor Relations Kenneth J. McGrath - Chief Financial Officer Conference Call Participants Noah Lewis - Raymond James & Associates, Inc., Research Division Operator Good day, and t...

BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.

OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisit...